SCHEMBL3017188

SCHEMBL3017188

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.46
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
REV1 Q9UBZ9 1/20 0.42
MAPT P10636 12/20 0.42
LMNA P02545 6/20 0.42
ALDH1A1 P00352 6/20 0.42
HSD17B10 Q99714 4/20 0.42
MAPK1 P28482 4/20 0.42
TP53 P04637 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
NPC1 O15118 3/20 0.42
GAA P10253 3/20 0.42
NFKB1 P19838 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999117 0.93 REV1 (0.50) ARRAB9ASMN1; SMN2REV1MAPT
SCHEMBL3015406 0.93 AR (0.47) ARRAB9ASMN1; SMN2CYP1A1CYP1B1
SCHEMBL3005637 0.90 AR (0.44) ARRAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3022472 0.88 AR (0.52) ARRAB9ASMN1; SMN2CYP1A1CYP1B1
SCHEMBL3017330 0.87 AR (0.46) ARRAB9ASMN1; SMN2CYP1A1CYP1B1
SCHEMBL3013756 0.87 AR (0.46) ARRAB9ASMN1; SMN2CYP1A1CYP1B1
SCHEMBL2998079 0.87 MAPT (0.52) ARRAB9ASMN1; SMN2CYP1A1CYP1B1
SCHEMBL3014625 0.87 MAPT (0.56) RAB9ASMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL3009532 0.87 SMN1; SMN2 (0.58) ARRAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3006321 0.87 AR (0.51) ARRAB9ASMN1; SMN2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.